Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Effectiveness of Suzetrigine (VX-548) for Acute Pain
NCT05661734Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of suzetrigine in acute pain, sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). Started Jan 2023; status: completed.
02
Drugs
suzetrigine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT05661734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661734.